Identifying Novel Targets for Recruitment of Brown Adipocytes

确定招募棕色脂肪细胞的新目标

• 批准号: 8524557
• 负责人: Olivier Boss
• 金额: $ 16.89万
• 依托单位: ENERGESIS PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8524557
• 关键词: Adipocytes; Adult; Animal Model; Atrophic; Biological Assay; Body Temperature; Body Weight decreased; Brown Fat; Cardiovascular Diseases; Cell Differentiation process; Cellular Assay; Collection; Data; Desire for food; Detection; Development; Diabetes Mellitus; Dyslipidemias; Energy Intake; Energy Metabolism; Epidemic; Exhibits; Exposure to; Fatty acid glycerol esters; Fluorescence; Future; Generations; Glucose; Heating; Human; Immunohistochemistry; Individual; Lead; Libraries; Maintenance; Measures; Messenger RNA; Metabolic; Mitochondria; Molecular; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Operative Surgical Procedures; Pharmaceutical Preparations; Phase; Play; Population; Positron-Emission Tomography; Proteins; Reproducibility; Resistance; Reverse Transcription; Rodent; Rodent Model; Role; Signal Transduction; Skeletal Muscle; Specificity; Stem cells; System; Temperature; Testing; Thermogenesis; Thinness; Time; Tissues; Weight maintenance regimen; Weight-Loss Drugs; Work; adipocyte differentiation; base; cellular targeting; cold temperature; drug development; energy balance; flexibility; insight; lipid biosynthesis; mitochondrial uncoupling protein; novel; progenitor; public health relevance; screening; tool; uncoupling protein 1; weight maintenance

DESCRIPTION (provided by applicant): Obesity has reached epidemic proportions in the U.S. and plays a major role in the development of type 2 diabetes, dyslipidemia, and cardiovascular disease. There remains a very significant need for better non- surgical treatments. While most weight loss agents rely on suppressing appetite to reduce caloric intake, strategies that can safely enhance metabolic rate, a previously unrealized approach to weight loss or weight maintenance, have potential to effectively treat obesity. Brown adipocytes have an extremely high metabolic rate because they express mitochondrial uncoupling protein-1 (UCP1). This protein dissipates the electrochemical gradient in the mitochondria of brown adipocytes as heat. Brown adipose tissue (BAT) thermogenesis is increased upon exposure to low temperatures, and plays an important role in the maintenance of body temperature and energy balance in rodents. BAT is also a flexible tissue that normally enlarges or atrophies over time depending on environmental temperature. In many different rodent models, enhancement of BAT mass has convincingly been shown to lead to weight loss and diabetes resistance. While BAT was until recently thought to be effectively nonexistent in adult humans, recent data obtained with PET imaging shows that adults in fact have significant BAT, and that this tissue is functional. Other data demonstrates that the amount of active BAT in individuals is strongly correlated with leanness. Until recently no brown adipocyte stem cell had been identified. We discovered a population of human skeletal muscle-resident brown adipocyte progenitors that under appropriate conditions become fully functional brown adipocytes. Following differentiation, these cells have high levels of UCP1 and a very high metabolic rate. This unique human progenitor population can now be utilized to identify molecular actors involved in human brown adipogenesis. We believe that some of the mechanisms/targets of existing drugs and other compounds may be involved in brown adipogenesis, and our preliminary data demonstrates this on a small scale. Here we propose to develop a novel high content assay system and deploy it to screen a library of compounds with known targets and cellular mechanisms of action. In doing so we anticipate that this unique assay system may uncover targets previously unsuspected of being involved in brown adipocyte recruitment. This work could therefore provide important insights for directing future drug development aimed at increasing brown fat in humans. If this Phase I project is successful, we plan subsequently to further characterize mechanisms with practical potential for further development by determining their specificity for and contributions o brown adipogenesis. We will then identify more potent and specific compounds based on these findings and test the best compounds in animal models of obesity.

描述（由申请人提供）：肥胖在美国已达到流行趋势，并且在 2 型糖尿病、血脂异常和心血管疾病的发展中发挥着重要作用。仍然非常需要更好的非手术治疗。虽然大多数减肥药物依靠抑制食欲来减少热量摄入，但可以安全提高代谢率的策略（一种以前未实现的减肥或体重维持方法）有可能有效治疗肥胖。棕色脂肪细胞具有极高的代谢率，因为它们表达线粒体解偶联蛋白-1 (UCP1)。这种蛋白质以热量的形式消散棕色脂肪细胞线粒体中的电化学梯度。棕色脂肪组织（BAT）的生热作用在暴露于低温时会增加，在啮齿动物维持体温和能量平衡中发挥着重要作用。 BAT 也是一种柔性组织，通常会随着时间的推移而扩大或萎缩，具体取决于环境温度。在许多不同的啮齿动物模型中，BAT 质量的增加已被令人信服地证明可以导致体重减轻和糖尿病抵抗。虽然直到最近 BAT 还被认为在成年人体内实际上不存在，但最近通过 PET 成像获得的数据表明，成年人实际上具有显着的 BAT，并且该组织具有功能。其他数据表明，个体中活跃 BAT 的数量与瘦削程度密切相关。直到最近还没有鉴定出棕色脂肪细胞干细胞。我们发现了一群人类骨骼肌驻留的棕色脂肪细胞祖细胞，在适当的条件下，它们会变成功能齐全的棕色脂肪细胞。分化后，这些细胞具有高水平的 UCP1 和非常高的代谢率。这种独特的人类祖细胞群现在可用于识别参与人类棕色脂肪形成的分子作用者。我们相信，现有药物和其他化合物的一些机制/靶点可能与棕色脂肪生成有关，我们的初步数据在小范围内证明了这一点。在这里，我们建议开发一种新型高内涵测定系统，并将其用于筛选具有已知靶点和细胞作用机制的化合物库。在此过程中，我们预计这种独特的检测系统可能会发现以前未被怀疑参与棕色脂肪细胞募集的目标。因此，这项工作可以为指导未来旨在增加人类棕色脂肪的药物开发提供重要的见解。如果第一阶段项目成功，我们计划随后通过确定其对棕色脂肪生成的特异性和贡献来进一步表征具有进一步开发的实际潜力的机制。然后，我们将根据这些发现确定更有效和更具体的化合物，并在肥胖动物模型中测试最佳化合物。